United Cannabis (CNABQ) 10-Q 19 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 19, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Entity Registrant Name	'United Cannabis Corp	'
Entity Central Index Key	'0001436161	'
Current Fiscal Year End Date	'--12-31	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	43,850,000

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$189,357	$32,414
Accounts receivable	16,113	'
Investments in non-marketable equity securities	300,000	'
Due from related party	'	8,862
Prepaid expenses and other assets	188,450	'
Assets of discontinued operations	'	17,616
Total current assets	693,920	58,892
Investments in non-marketable equity securities	593,750	'
Equity method investments	282,000	'
Notes and interest receivable	1,263,150	'
Total assets	2,832,820	58,892
Current liabilities:	'	'
Accounts payable	38,571	'
Accrued expenses	130,452	'
Derivative liability	165,488	'
Current portion of deferred revenue	444,000	'
Note payable	175,000	'
Current portion of convertible note payable, net	47,083	'
Convertible note payable, related party	'	50,000
Total current liabilities	1,000,594	50,000
Long term liabilities:	'	'
Deferred revenue, net of current portion	518,750	'
Convertible note payable, net and net of current portion	715,918	'
Total liabilities	2,235,262	50,000
Stockholders' equity:	'	'
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding	'	'
Common stock, no par value; 100,000,000 shares authorized; 43,800,000 (unaudited) and 6,020,000* issued and outstanding, respectively	2,006,019	165,495
Common stock not yet issued, 40,000 shares	88,000	'
Accumulated deficit	-1,496,461	-156,603
Total stockholders' equity	597,558	8,892
Total liabilities and stockholders' equity	$2,832,820	$58,892

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CONDENSED BALANCE SHEETS [Abstract]	'	'
Preferred stock, no par value	'	'
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, no par value	'	'
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,800,000	6,020,000	[1]
Common stock, shares outstanding	43,800,000	6,020,000	[1]
Common stock, not yet issued shares	40,000	40,000
[1]	The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
CONDENSED STATEMENTS OF OPERATIONS [Abstract]	'	'		'		'
Revenue	$91,113	'		$91,113		'
Cost of goods sold	2,136	'		2,136		'
Gross profit	88,977	'		88,977		'
Operating expenses:	'	'		'		'
Sales and marketing	20,205	'		94,363		'
Research and development	94,751	'		170,805		'
General and administrative	522,421	21,694		946,562		32,471
Total operating expenses	637,377	21,694		1,211,730		32,471
Loss from operations	-548,400	-21,694		-1,122,753		-32,471
Other income (expense):	'	'		'		'
Interest income	13,154	'		13,179		'
Loss on derivative liability	-1,942	'		-1,942		'
Interest expense	-67,488	'		-67,488		'
Loss on origination of derivative liability	-12,810	'		-12,810		'
Amortization of debt discount	-89,152	'		-89,152		'
Total other income (expense)	-158,238	'		-158,213		'
Loss from continuing operations	-706,638	-21,694		-1,280,966		-32,471
Net income (loss) from discontinued operations	'	-5,578		-58,892		14,244
Net loss	($706,638)	($27,272)		($1,339,858)		($18,227)
Net loss per share from continuing operations:	'	'		'		'
Basic and diluted	($0.02)	$0	[1]	($0.03)		$0	[1]
Net income (loss) per share from discontinued operations:	'	'		'		'
Basic and diluted	'	$0	[1]	$0	[1]	$0	[1]
Net income (loss) per common share:	'	'		'		'
Basic and diluted	($0.02)	$0	[1]	($0.03)		$0	[1]
Basic and diluted weighted-average common shares outstanding:	43,656,304	6,020,000	[2]	43,389,744		6,020,000	[2]
[1]	Denotes income or loss of less than $0.01 per share.
[2]	The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities:	'	'
Net loss	($1,339,858)	($18,227)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Depreciation - assets of discontinued operations	'	20,299
Loss on sale of assets of discontinued operations	15,704	'
Management fees and reimbursement of expenses, related parties, net, of discontinued operations	'	-38,389
Amortization of debt discount	89,152	'
Non-cash interest expense	11,609	'
Convertible note payable issued for debt issuance costs	32,500	'
Loss on origination of derivative liability	12,810	'
Shares issued for services	34,000	'
Value of non-marketable equity securities recognized as revenue	-75,000	'
Loss on revaluation of derivative liability	1,942	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-16,113	'
Interest receivable	-13,150	'
Due from related party	10,774	'
Inventory	'	-3,026
Due to related party	'	5,445
Prepaid expenses	-26,450	'
Accounts payable and accrued expenses	169,023	10,838
Net cash provided by (used in) operating activities	-1,093,057	-23,060
Investing activities:	'	'
Equity method investments	-50,000	'
Equipment purchases related to discontinued operations	'	-18,215
Net cash provided by (used in) investing activities	-50,000	-18,215
Financing activities:	'	'
Net proceeds from issuance of convertible debt and warrants	225,000	'
Proceeds from issuance of note payable	175,000	'
Repayment of notes payable, related party	'	-50,000
Proceeds from convertible note payable, related party	'	50,000
Proceeds from issuance of common shares	900,000	'
Net cash provided by (used in) financing activities	1,300,000	'
Net increase (decrease) in cash	156,943	-41,275
Cash, beginning of period	32,414	76,445
Cash, end of period	189,357	35,170
Supplemental schedule of cash flow information:	'	'
Cash paid for interest	'	'
Cash paid for income taxes	'	'
Supplemental disclosure of non-cash investing and financing activities:	'	'
Investment in non-marketable equity securities received as consideration for deferred services	893,750	'
Investment in equity method investments received as consideration for deferred services	144,000	'
Investment in equity method investments received for commitment to issue common stock	88,000	'
Issuance of common stock for prepaid professional fees	162,000	'
Acquisition of notes receivable funded by convertible note payable	1,250,000	'
Issuance of convertible note payable for debt issuance costs	32,500	'
Warrants issued for debt discount	694,525	'
Debt conversion feature issued for debt discount	151,937	'
Debt conversion feature issued for interest payable discount	11,609	'
Conversion of note payable, related party, into common stock	$50,000	'

BUSINESS_ORGANIZATION_AND_NATU

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2014
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]	'
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	'
	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS
	Current Operations and Background – United Cannabis Corporation ("we", "our", "us" or "UCC") a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. UCC was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCC, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.
	On March 26, 2014, we entered into a License Agreement with Earnest Blackmon ("Blackmon"), Tony Verzura ("Verzura") and Chad Ruby ("Ruby") pursuant to which Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.
	In connection with this transaction:
	•	Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid (cannabidol or "CBD") therapy program called "A.C.T. Now", security, regulatory compliance, and any other methods and processes which relate to the cannabis industry.
	•	The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.
	•	Blackmon, Verzura and Ruby were appointed to our board of directors effective April 8, 2014.
	•	Blackmon was elected as our President, Ruby was elected as Chief Operating Officer and Verzura was elected as Vice President. On June 24, 2014, Blackmon was elected as our CEO and CFO.
	•	A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.
	As a result of this transaction our business plan has changed. We are beginning to create partnerships with businessmen, entrepreneurs, scientists and others, both domestically and internationally, for the purpose of developing cannabis-based products worldwide.
	For example, we are starting to enter into licensing and consulting agreements with partners who desire to license our entire turnkey seed-to-sale business model in jurisdictions where it is legal to do so, and we plan to typically receive a percentage of their gross revenues as our fee. In addition to licensing our intellectual property, we are offering consulting services on the design and buildout of cultivation facilities; we offer training and staffing services; and we will assist our partners in finding the right locations for cultivation facilities. We provide our partners access to our genetic catalogue which includes over 15 CBD strains, over 150 THC strains and over 30 Cannabis Cup winners.
	We also provide our partners access to our full range of extracted/infused medical products. Our plan includes licensing our intellectual property for whole plant activated oils, smokable concentrates, infused products, topical lotions, pills, sublingual transdermal patches and our partners will have access to future technology and products that we develop.
	Our goals are to establish strong cultivation positions through our local partners in markets where it is legal and use these revenues to develop new cannabinoid based drugs for clinical FDA approval patents.
	On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.
	Government Regulation - Marijuana is a Schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.
	As of November 19, 2014, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado, Washington, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana.   However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously.  Any such change in the federal government's enforcement of current federal laws could cause significant financial damage to us.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2014 and 2013, are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.
	Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.
	We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
	Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.
	The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of the notes payable and notes receivable at September 30, 2014, approximate their respective fair values based on our incremental borrowing rates.
	Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2014 and December 31, 2013.
	Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.
	We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of September 30, 2014 and December 31, 2013.
	Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other assets.
	Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.
	Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.
	Equity Method Investments – Our investments in entities representing ownership of at least 15% but less than 50%, where we exercise significant influence, are accounted for under the equity method.
	Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.
	Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.
	Advertising Costs - All advertising costs are expensed as incurred.
	Research and Development Expense - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.
	Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.
	Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.
	We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.
	Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.
	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Convertible notes		337,569			—			337,569			—
	Warrants to purchase common stock		997,692			—			3,997,692			—
	Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.
	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.
	Percentage of Revenue during the Period Ended
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Customer A		82	%		—			82	%		—
	Customer B		10	%		—			10	%		—
	Percentage of Accounts Receivable during the Period Ended
		September 30,			December 31,
		2014			2013
	Customer B		43	%			—
	Customer C		57	%			—
	Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2014
GOING CONCERN [Abstract]	'
GOING CONCERN	'
	NOTE 3 – GOING CONCERN
	Our condensed financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2014, we incurred losses of $1,339,858 and used cash of $1,093,057 in our operating activities. As at September 30, 2014, we had a working capital deficit of $306,674 and an accumulated deficit of $1,496,461.  Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

INVESTMENTS_IN_NONMARKETABLE_E

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	9 Months Ended
	Sep. 30, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]	'
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	'
	NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES
	On May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. (“WMD”), a Canadian private company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represent a 4.29% equity investment in WMD and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at the estimated cost, based on our estimate of the fair value of the securities we received on the date of the transaction.
	The warrants entitle us to purchase WMD shares for CDN $0.50 each for a period of nine months from the date the warrant was issued. In addition, we are required to exercise all of these warrants if the holders of our Series A Warrants (see Note 14 below) exercise a minimum of 800,000 of our Series A Warrants prior to the expiration of the WMD warrants.
	The WMD common shares were recorded at $0.50 per share based on WMD's most recent sale of their common shares prior to the date of the transaction (CDN $0.50).
	The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the nine months ended September 30, 2014:
	Risk free interest rate	0.6	%
	Expected term (years)	0.5
	Expected volatility	70	%
	Expected dividends	0	%
	The $300,000 fair value assigned as the cost to the WMD warrants has been classified as a current asset as the warrants expire after nine months, while the $593,750 assigned to the cost of the WMD common shares has been classified as a long term asset as these shares do not expire.

PREPAID_EXPENSES_AND_OTHER_ASS

PREPAID EXPENSES AND OTHER ASSETS	9 Months Ended
	Sep. 30, 2014
PREPAID EXPENSES AND OTHER ASSETS [Abstract]	'
PREPAID EXPENSES AND OTHER ASSETS	'
	NOTE 5 – PREPAID EXPENSES AND OTHER ASSETS
	Prepaid expenses and other assets consist of:
		September 30,		December 31,
		2014		2013
	Prepaid investor relations services	$	162,000	$	—
	Prepaid accounting fees		550		—
	Interest receivable		25,900		—
		$	188,450	$	—

EQUIPMENT

EQUIPMENT	9 Months Ended
	Sep. 30, 2014
EQUIPMENT [Abstract]	'
EQUIPMENT	'
	NOTE 6 – EQUIPMENT
	Our equipment consists of the following at:
	September 30,		December 31,
	2014		2013
	Equipment	$	—	$	131,584
	Less accumulated depreciation		—		(113,968	)
		$	—	$	17,616

EQUITY_METHOD_INVESTMENTS

EQUITY METHOD INVESTMENTS	9 Months Ended
	Sep. 30, 2014
EQUITY METHOD INVESTMENTS [Abstract]	'
EQUITY METHOD INVESTMENTS	'
	NOTE 7 – EQUITY METHOD INVESTMENTS
	Our equity method investments consist of:
		September 30,		December 31,
		2014		2013
	Lone Mountain Partners, LLC – 25% interest	$	50,000	$	—
	Om of Medicine, LLC – 15% interest		45,000		—
	OM of Illinois, LLC – 33% interest		99,000		—
	Cannibinoid Research & Development Company Limited – 50%		88,000		—
	Total equity method investments	$	282,000	$	—
	On August 14, 2014, we acquired a 25% membership interest in Lone Mountain Partners, LLC, (“Lone Mountain”) for $50,000 and a commitment to provide future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Nevada and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of Lone Mountain. As of September 30, 2014, Lone Mountain did not have any operations or operating activities. We accounted for the $50,000 cash contribution as an equity method investment on our condensed balance sheet.
	On August 15, 2014, and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC (together the “Oms”), respectively, in return for a commitment to provide $144,000 of future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Illinois and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of the Oms. As of September 30, 2014, the Oms did not have any operations or operating activities. We accounted for this $144,000 commitment to provide services as deferred revenue in our condensed statements of operations and included this amount in equity method investments on our condensed balance sheets.
	On August 15, 2014, we acquired a 50% interest in Cannibinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day's closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as our intellectual property in the operations of CRD. As of September 30, 2014, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our condensed balance sheet. As we have not yet issued the 40,000 shares, the $88,000 is classified as common stock not yet issued on our condensed balance sheets.

NOTES_AND_INTEREST_RECEIVABLE

NOTES AND INTEREST RECEIVABLE	9 Months Ended
	Sep. 30, 2014
NOTES AND INTEREST RECEIVABLE [Abstract]	'
NOTES AND INTEREST RECEIVABLE	'
	NOTE 8 – NOTES AND INTEREST RECEIVABLE
	Notes Receivable
	On August 13, 2014, in conjunction with the $1,657,500 Typenex Co-Investment, LLC (“Typenex”) convertible promissory note more fully described in Note 12 below, we received five, unsecured, $250,000 Investor Notes bearing interest at 8% per annum, totaling $1,250,000 that mature with respect to principal and interest on September 13, 2016. The Investor Notes can be prepaid at any time, without penalty, by Typenex and Typenex has certain rights to offset the amounts owed to us by amounts we owe to them in accordance with the terms of the Investor Notes. We have the right to call the Investor Notes if the share price of our common stock (as further defined in the Investor Notes terms and conditions) exceeds $6.00 per share for 20 consecutive trading days.
	Our intention in entering into this arrangement with Typenex is that the Investor Notes will provide us with a mechanism to obtain additional cash funding. Upon our request and with Typenex's consent, we can redeem individual Investor Notes for cash before meeting the price threshold of $6.00 per share for 20 consecutive days at which point we have the right to demand repayment of these Investor Notes from Typenex without requiring their consent.
	During the three and nine months ended September 30, 2014, we recognized $13,150 of interest income applicable to these Investor Notes and this amount is included in notes and interest receivable on our condensed balance sheets.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2014
FAIR VALUE MEASUREMENTS [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 9 – FAIR VALUE MEASUREMENTS
	We have adopted the guidance of ASC 820, Fair Value Measurement, which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The following table provides our liabilities carried at fair value measured on a recurring basis as of September 30, 2014:
		Level 1		Level 2		Level 3		Total
	Derivative liability	$	—	$	—	$	165,488	$	165,488
	We did not have any liabilities carried at fair value measured on a recurring basis as of December 31, 2013.
	We value our derivative instruments related to embedded conversion features from the initial borrowing of $282,500 under the Typenex convertible note payable (see Note 12 below) and accrued interest of $21,312 thereon in accordance with the Level 3 guidelines. For the nine month period ended September 30, 2014, the following table reconciles the beginning and ending balances for financial instruments that are carried at fair value measured on a recurring basis:
	Derivative liability as of December 31, 2013	$	—
	Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
	Additions to derivative liability for interest payable conversion feature recorded as interest expense		11,609
	Loss on revaluation of derivative liability at period end		1,942
	Derivative liability as of September 30, 2014	$	165,488
	The fair values of embedded conversion features issued with our convertible debt and accrued interest payable were estimated using the Black-Scholes option pricing model. The key inputs to this valuation model during the nine months ended September 30, 2014, were as follows:
	Risk-free interest rate			0.43% – 0.58%
	Dividend yield			—
	Volatility			146% – 157%
	Expected life in years			1.96 – 2.09
	Exercise price			$3.00
	The following tabular presentation reflects the components of derivative financial instruments on our condensed balance sheets at September 30, 2014 and December 31, 2013:
		September 30,		December 31,
		2014		2013
	Derivative Liabilities:
	Embedded derivative liability in convertible debt	$	153,879	$	—
	Embedded derivative liability in interest payable		11,609		—
	Total derivative liability	$	165,488	$	—

DEFERRED_REVENUE

DEFERRED REVENUE	9 Months Ended
	Sep. 30, 2014
DEFERRED REVENUE.	'
DEFERRED REVENUE.	'
	NOTE 10 – DEFERRED REVENUE
	Our deferred revenue consists of:
		September 30,		December 31,
		2014		2013
	Deferred revenue – WeedMD	$	818,750	$	—
	Deferred revenue - Om of Medicine, LLC		45,000		—
	Deferred revenue - OM of Illinois, LLC		99,000		—
	Less – current portion		-444,000		—
	Total equity method investments	$	518,750	$	—
	As described in Note 4 above, on May 30, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and, based on discussions with WMD, we expect to deliver consulting services and use of our intellectual property to WMD on a consistent monthly basis during a three year period beginning June 1, 2014. Accordingly, we began recognizing $25,000 of deferred revenue per month totaling $75,000 during the three and nine months ending September 30, 2014. At September 30, 2014, we expect to recognize $300,000 of the $818,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $300,000 as a current liability on our condensed balance sheets.
	As described in Note 7 above, on August 15, 2014 and August 31, 2014, we acquired a 15% and 33% membership interest in Om of Medicine, LLC and OM of Illinois, LLC, respectively, in return for a commitment to provide $144,000 of future services to these entities. As of September 30, 2014, the Oms did not have any operations or operating activities; however, we expect to satisfy our future service obligations during the next twelve months and accordingly, we have classified the $144,000 as a current liability in our condensed balance sheets.

NOTES_PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2014
NOTES PAYABLE [Abstract]	'
NOTES PAYABLE	'
	NOTE 11 – NOTES PAYABLE
	On July 7, 2014, we issued a $175,000, unsecured, demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. Interest expense during the three and nine months ending September 30, 2014, was $2,067 and accrued interest payable in that amount is included in accrued expenses on our condensed balance sheets.

CONVERTIBLE_NOTE_PAYABLE

CONVERTIBLE NOTE PAYABLE	9 Months Ended
	Sep. 30, 2014
CONVERTIBLE NOTE PAYABLE	'
CONVERTIBLE NOTE PAYABLE	'
	NOTE 12 – CONVERTIBLE NOTE PAYABLE
	Our convertible note payable consists of the following:
		September 30,			December 31,
		2014			2013
	Convertible note payable-Typenex	$	1,657,500		$	—
	Less – current portion		(282,500	)		—
	Convertible note payable-noncurrent		1,375,000			—
	Less – unamortized discount		(659,082	)		—
	Convertible note payable-noncurrent, net	$	715,918		$	—
	Convertible note payable-current portion	$	282,500		$	—
	Less – unamortized discount		(235,417	)		—
	Convertible notes payable-current portion, net	$	47,083		$	—
	On August 13, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of a 10% convertible promissory note (the “Note”) in the principal amount of $1,657,500 (the “Closing Amount”) convertible into shares of our common stock. The Note has an original issue discount (“OID”) of $150,000. Typenex retained $7,500 of the Closing Amount for due diligence and legal bills related to the transaction and paid $25,000 on our behalf to a third party for brokerage fees (together, the “Fees”). The financing closed on August 13, 2014 (the “Closing Date”).
	In addition, we issued to Typenex warrants (the “Warrants”) to purchase 997,692 shares of our common stock, subject to adjustment in the event of a cashless exercise, as defined in the Warrant. Warrants for 170,044 shares were immediately exercisable with the remainder only becoming exercisable, in five tranches, if and when the Investor Notes (see Note 8 above) are paid. The Warrants are exercisable at $3.00 per share (the “Exercise Price”) for a period of three years on a cash or cashless basis. If we, at any time while the Warrants are outstanding, sell or issue our common stock or securities convertible into or exercisable for shares of our common stock, including common stock issued under the Note, at an effective price per share less than the Exercise Price, then, subject to a few exceptions set forth in the Warrant, the Exercise Price will be reduced to such lower price provided that the number of shares of common stock issuable under the Warrant may not exceed a number of shares equal to three times the number of shares of common stock issuable under the Warrants as of the Closing Date.
	The Note bears interest at the rate of 10% per annum. All interest and principal must be paid twenty-five months after the date of the first borrowing under the Note (the “Maturity Date”). The outstanding balance on the Note is convertible into common stock, at Typenex's option, at $3.00 per share (the “Optional Conversion”).
	Beginning on the date that is six months after the date of the first borrowing and on the same day of each month thereafter until the Maturity Date, we must pay to Typenex the lesser of (i) $82,875, plus the sum of any accrued and unpaid interest, or (ii) the then outstanding balance under the Note. Payments of each installment amount may be made in cash or, as long as we are in compliance with certain terms and conditions set forth in the Note, by converting such installment amount into our common stock. The conversion price for each installment conversion will be the lesser of (i) the $3.00, and (ii) 70% (the “Conversion Factor”) of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion (the “Market Price”), provided that if at any time the average of the three lowest closing bid prices in the 20 trading days immediately preceding any date of measurement is below $1.00, then in such event the then-current Conversion Factor shall be reduced to 65% for all future Conversions, subject to other reductions set forth in the Note. In the event we elect to prepay all or any portion of the Note, we are required to pay to Typenex an amount in cash equal to 125% multiplied by the sum of all principal, interest and any other amounts owing. The Note is secured by all of our assets.
	On a date that is 20 trading days from each date that we deliver conversion shares to Typenex, there is a true-up date in which we will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.
	On August 15, 2014, we received net cash proceeds from our initial borrowing under the Note of $225,000 as follows: total initial borrowing of $282,500 less the $32,500 of Fees and OID applicable to the initial borrowing of $25,000. We expensed the Fees immediately as interest expense as the initial borrowing and all subsequent tranches were immediately convertible into our common stock by the lender.
	In addition, Typenex has the option to convert all or any part of the outstanding balance of principal, interest, OID and other fees (the “Conversion Feature”) in six tranches; an initial tranche of $282,500 plus interest and other fees owed and five subsequent tranches of $275,000 plus interest and other fees owed for an aggregate total of $1,657,500 plus interest and other fees owed at a conversion price of $3.00 per share. Currently, only the $282,500 initial tranche is conversion eligible. The five subsequent $275,000 tranches become conversion eligible if and when Typenex repays to us the corresponding $250,000 Investor Note(s).
	With regards to our $282,500 initial borrowing, on August 15, 2014, we recorded the $25,000 of OID plus the $118,373 fair value of the first Warrant issued, plus $139,127 of the $151,937 fair value of the initial borrowing conversion feature, or, in total, $282,500, as debt discount and recorded the excess, $12,810, as loss on origination of derivative liability in our condensed statements of operations. We are amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.
					Nine Months Ended
					September 30,
					2014
	Debt discount - OID				$	25,000
	Debt discount – Warrant #1					118,373
	Debt discount – conversion feature					151,937
	Less: loss on origination of derivative					(12,810	)
	Debt discount – beginning balance					282,500
	Less: amortization of debt discount					(47,083	)
	Unamortized debt discount – end of period				$	235,417
	With regards to the remaining $1,375,000 owed under the Note, we recorded the remaining $125,000 of OID plus the $576,151 fair value of the remaining Warrants issued, or, in total, $701,151, as debt discount. We are amortizing the $701,151 debt discount on a straight line basis, which approximates the effective interest method, over the twenty-five month term of the Note.
	Our unamortized debt discount applicable to the noncurrent portion of the Note consists of:
					Nine Months Ended
					September 30,
					2014
	Debt discount - OID				$	125,000
	Debt discount – Warrants #2 - #6					576,151
	Debt discount – beginning balance					701,151
	Less: amortization of debt discount					(42,069	)
	Unamortized debt discount – end of period				$	659,082
	Our convertible note, net consists of:
					Nine Months Ended
					September 30,
					2014
	Note				$	1,657,500
	Debt discount – OID					(150,000	)
	Debt discount – Warrants					(694,524	)
	Debt discount – conversion feature					(151,937	)
	Debt discount – conversion feature expensed as loss on origination of derivative					12,810
	Convertible note, net – beginning of period					673,849
	Amortization of debt discount					89,152
	Convertible note, net – end of period				$	763,001
	During the three and nine months ended September 30, 2014, we recorded debt discount amortization and interest expense of $89,152 and $21,312, respectively, applicable to this Note.
	The fair value of the conversion feature applicable to the $21,312 of accrued interest was $11,609 and this amount was recorded as interest expense and an increase to our derivative liability in our condensed financial statements.

NOTES_PAYABLE_RELATED_PARTIES

NOTES PAYABLE, RELATED PARTIES	9 Months Ended
	Sep. 30, 2014
NOTES PAYABLE, RELATED PARTIES [Abstract]	'
NOTES PAYABLE, RELATED PARTIES	'
	NOTE 13 – NOTES PAYABLE, RELATED PARTIES
	In December 2011, we entered into a Revolving Promissory Note (the “Revolving Note”) with Ms. Stoppenhagen, our former president and director. Under the terms of the Revolving Note, Ms. Stoppenhagen agreed to advance us, from time to time and at our request, amounts up to an aggregate of $100,000 until December 31, 2013, with all advances be paid on or before December 31, 2013, and interest accruing from the date of any advances on any principal amount withdrawn, and on unpaid interest thereon, at the rate of six percent (6%) per annum, compounded annually. As of September 30, 2014 and December 31, 2013, nothing was owed under the Revolving Note.
	On September 30, 2013, we issued a Convertible Note (the "Convertible Note") for $50,000 to NYX Capital Advisors, Inc. (“NYX”), an entity owned by Ms. Stoppenhagen's husband, in connection with $50,000 cash paid by NYX.  The Convertible Note bears no interest and was convertible at any time, at the option of the holder, into 10,000,000 shares of our common stock at $0.005 per share.  The Convertible Note was converted into our common shares on February 24, 2014.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 14 – STOCKHOLDERS' EQUITY
	Change of control
	On February 27, 2014, NYX and Mr. Paul Enright, our former President, entered into a Stock Purchase Agreement, pursuant to which NYX sold to Mr. Enright an aggregate of 10,000,000 shares of our common stock, representing approximately 87% of our issued and outstanding shares as of that date.
	Stock split
	On March 21, 2014, we effected a four-for-one stock split of our common stock in the form of a stock dividend of three shares of common stock for each share of common stock outstanding to stockholders of record on March 19, 2014.
	Equity offering
	On March 26, 2014, we sold 600,000 units for a total amount of $900,000 to 45 accredited investors. Each Unit consisted of one share of our common stock, two A Warrants and three B Warrants. Each A Warrant entitles the holder to purchase one share of our common stock at a price of $7.50 per share during the two year period commencing April 1, 2014, and the A Warrants are callable once our common stock has traded at a price of at least $15.00 for 20 consecutive trading days.  Each B Warrant entitles the holder to purchase one share of our common stock at a price of $15.00 per share during the three year period commencing April 1, 2014, and the B Warrants are callable once our common stock has traded at a price of at least $22.00 for 20 consecutive trading days.
	Change in Authorized Share Capital
	Effective May 2, 2014, we increased the authorized number of our preferred shares from five million to ten million and the authorized number of our common shares from 50 million to 100 million. At the same time we also changed the par value of both our preferred and common stock from $0.001 per share to no par value per share.
	Common Stock Issued For Services
	On August 14, 2014, we issued 10,000 shares of common stock valued at $9,200, based on the previous trading day's closing price as consideration for marketing services. The $9,200 is included in included in sales and marketing expense in our condensed statements of operations.
	On August 15, 2014, we issued 20,000 shares of common stock valued at $24,800, based on the previous trading day's closing price as consideration for consulting services. The $24,800 is included in included in general and administrative expense in our condensed statements of operations.
	On August 25, 2014, we committed to issued 40,000 shares of common stock valued at $88,000, based on the previous trading day's closing price as consideration for a 50% ownership interest in CRD. The $88,000 is included in included in equity method investments on our condensed balance sheets. The $88,000 of common stock is included in common stock yet to be issues on our condensed balance sheets.
	On September 17, 2014, we issued 150,000 shares of common stock valued at $162,000, based on the previous trading day's closing price as consideration for prepaid investor relations services. The $162,000 is included in prepaid expenses and other assets on our condensed balance sheets.
	Warrants:
	The following table summarizes our share warrants outstanding as of September 30, 2014 and December 31, 2013:
		30-Sep-14
		Number of		Weighted		Weighted
		Shares		Average		Average
				Remaining		Exercise
				Life		Price
				(years)
	Warrants outstanding, beginning of period		—		—	$	—
	Issued		3,997,692		1.8		9.75
	Exercised		—		—		—
	Expired		—		—		—
	Warrants outstanding, end of period		3,997,692		1.8	$	9.75
	Warrants exercisable, September 30, 2014		3,170,044		1.6	$	11.52

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	NOTE 15 –COMMITMENTS AND CONTINGENCIES
	Contractual Obligations and Commercial Commitments
	On May 6, 2014, we entered into a consultancy agreement with two third party doctors that has a nine month term which can be renewed and/or extended by mutual agreement.  The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the three and nine months ended September 30, 2014, we have recognized $100,000 and $150,000 of the $200,000 cash payment obligations as research and development expenses in our condensed statements of operations. At September 30, 2014, $100,000 is included in accrued expenses on our condensed balance sheet. The value of the 100,000 shares will be recognized upon achievement of the goals, currently anticipated to be during the fourth quarter of 2014.
	Legal Proceedings
	We were not subject to any legal proceedings during the three and nine months ended September 30, 2014, and, to the best of our knowledge, no legal proceedings are pending or threatened.

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Sep. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
DISCONTINUED OPERATIONS	'
	NOTE 16 –DISCONTINUED OPERATIONS
	On March 31, 2014 we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.  See Note 1 for further detail on our change in operations.
	The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014			2013
	Revenues	$	—	$	32,278		$	20,684		$	91,144
	Operating expenses:
	Selling, general and administrative		—		30,870			63,872			56,601
	Depreciation		—		6,986			—			20,299
	Loss on disposal of assets		—		—			15,704			—
	Total operating expenses		—		37,856			79,576			76,900
	Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
	Provision for income taxes		—		—			—			—
	Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244
	Our assets held for sale consist of the following and are included in assets of discontinued operations on our condensed balance sheets:
		September 30,		December 31,
		2014		2013
	Equipment	$	—	$	17,616

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 17 – SUBSEQUENT EVENTS
	On October 22, 2014, we issued 50,000 shares of common stock valued at $24,000 based on the previous trading day's closing price as consideration for prepaid investor relations services.
	In accordance with ASC 855-10 we have analyzed its operations subsequent to September 30, 2014 to the date these condensed financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)

9 Months Ended

Sep. 30, 2014

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

'

Basis of Presentation

'

Basis of Presentation - We prepared these condensed financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”). The accompanying unaudited interim condensed financial statements have been prepared in accordance with GAAP for interim financial information in accordance with Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. Operating results for the three and nine month periods ended September 30, 2014 and 2013, are not necessarily indicative of the results for the full year. While we believe that the disclosures presented herein are adequate and not misleading, these interim condensed financial statements should be read in conjunction with the audited financial statements and the footnotes thereto contained in our annual report on Form 10-K for the year ended December 31, 2013.

Use of Estimates

'

Use of Estimates - The preparation of condensed financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed financial statements and the reported amounts of expenses during the periods presented.

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when the financial statements are prepared. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.

Financial Instruments

'

Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.

The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of the notes payable and notes receivable at September 30, 2014, approximate their respective fair values based on our incremental borrowing rates.

Cash and Cash Equivalents

'

Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of September 30, 2014 and December 31, 2013.

Accounts Receivable

'

Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.

We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of September 30, 2014 and December 31, 2013.

Investments in Non-Marketable Equity Securities

'

Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by an investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other assets.

Inventory

'

Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.

Equipment

'

Equipment - Equipment is stated at cost and is depreciated using the straight-line method over the estimated useful life of the asset, ranging from three to five years.

Equity Method Investments

'

Equity Method Investments – Our investments in entities representing ownership of at least 15% but less than 50%, where we exercise significant influence, are accounted for under the equity method.

Deferred Revenue

'

Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.

Revenue Recognition

'

Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Advertising Costs

'

Advertising Costs - All advertising costs are expensed as incurred.

Research and Development Expense

'

Research and Development Expense - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

Selling, General and Administrative Expenses

'

Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.

Income Taxes

'

Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.

We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' equity. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Interest associated with unrecognized tax benefits are classified as interest expense and penalties are classified in selling, general and administrative expenses in the statements of income.

Net Income (Loss) Per Share

'

Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.

Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.

Three Months Ended

Nine Months Ended

September 30,

September 30,

2014

2013

2014

2013

Convertible notes

337,569

—

337,569

—

Warrants to purchase common stock

997,692

—

3,997,692

—

Concentration of Credit Risk

'

Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution are not insured by the FDIC.

The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.

Percentage of Revenue during the Period Ended

Three Months Ended

Nine Months Ended

September 30,

September 30,

2014

2013

2014

2013

Customer A

82

%

—

82

%

—

Customer B

10

%

—

10

%

—

Percentage of Accounts Receivable during the Period Ended

September 30,

December 31,

2014

2013

Customer B

43

%

—

Customer C

57

%

—

Recently Issued Accounting Pronouncements

'

Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on the condensed financial statements upon adoption.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	'
	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Convertible notes		337,569			—			337,569			—
	Warrants to purchase common stock		997,692			—			3,997,692			—
Schedule of significant concentrations in revenues and accounts receivable	'
	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated.
	Percentage of Revenue during the Period Ended
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Customer A		82	%		—			82	%		—
	Customer B		10	%		—			10	%		—
	Percentage of Accounts Receivable during the Period Ended
		September 30,			December 31,
		2014			2013
	Customer B		43	%			—
	Customer C		57	%			—

INVESTMENTS_IN_NONMARKETABLE_E1

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]	'
Schedule of Fair Value Assumptions Used to Value Warrants	'
	The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions during the nine months ended September 30, 2014:
	Risk free interest rate	0.6	%
	Expected term (years)	0.5
	Expected volatility	70	%
	Expected dividends	0	%

PREPAID_EXPENSES_AND_OTHER_ASS1

PREPAID EXPENSES AND OTHER ASSETS (Tables)	9 Months Ended
	Sep. 30, 2014
PREPAID EXPENSES AND OTHER ASSETS [Abstract]	'
Schedule of prepaid expenses and other assets	'
	Prepaid expenses and other assets consist of:
		September 30,		December 31,
		2014		2013
	Prepaid investor relations services	$	162,000	$	—
	Prepaid accounting fees		550		—
	Interest receivable		25,900		—
		$	188,450	$	—

EQUIPMENT_Tables

EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2014
EQUIPMENT [Abstract]	'
Schedule of Equipment	'
	Our equipment consists of the following at:
	September 30,		December 31,
	2014		2013
	Equipment	$	—	$	131,584
	Less accumulated depreciation		—		(113,968	)
		$	—	$	17,616

EQUITY_METHOD_INVESTMENTS_Tabl

EQUITY METHOD INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
EQUITY METHOD INVESTMENTS [Abstract]	'
Schedule of equity method investments	'
	Our equity method investments consist of:
		September 30,		December 31,
		2014		2013
	Lone Mountain Partners, LLC – 25% interest	$	50,000	$	—
	Om of Medicine, LLC – 15% interest		45,000		—
	OM of Illinois, LLC – 33% interest		99,000		—
	Cannibinoid Research & Development Company Limited – 50%		88,000		—
	Total equity method investments	$	282,000	$	—

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2014
FAIR VALUE MEASUREMENTS [Abstract]	'
Schedule of liabilities carried at fair value measured on a recurring basis	'
	The following table provides our liabilities carried at fair value measured on a recurring basis as of September 30, 2014:
		Level 1		Level 2		Level 3		Total
	Derivative liability	$	—	$	—	$	165,488	$	165,488
Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis	'
	For the nine month period ended September 30, 2014, the following table reconciles the beginning and ending balances for financial instruments that are carried at fair value measured on a recurring basis:
	Derivative liability as of December 31, 2013	$	—
	Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
	Additions to derivative liability for interest payable conversion feature recorded as interest expense		11,609
	Loss on revaluation of derivative liability at period end		1,942
	Derivative liability as of September 30, 2014	$	165,488
Schedule of key inputs in valuation of embedded conversion features	'
	The key inputs to this valuation model during the nine months ended September 30, 2014, were as follows:
	Risk-free interest rate			0.43% – 0.58%
	Dividend yield			—
	Volatility			146% – 157%
	Expected life in years			1.96 – 2.09
	Exercise price			$3.00
Schedule of components of derivative financial instruments on condensed balance sheets	'
	The following tabular presentation reflects the components of derivative financial instruments on our condensed balance sheets at September 30, 2014 and December 31, 2013:
		September 30,		December 31,
		2014		2013
	Derivative Liabilities:
	Embedded derivative liability in convertible debt	$	153,879	$	—
	Embedded derivative liability in interest payable		11,609		—
	Total derivative liability	$	165,488	$	—

DEFERRED_REVENUE_Tables

DEFERRED REVENUE (Tables)	9 Months Ended
	Sep. 30, 2014
DEFERRED REVENUE.	'
Schedule of deferred revenue	'
	Our deferred revenue consists of:
		September 30,		December 31,
		2014		2013
	Deferred revenue – WeedMD	$	818,750	$	—
	Deferred revenue - Om of Medicine, LLC		45,000		—
	Deferred revenue - OM of Illinois, LLC		99,000		—
	Less – current portion		-444,000		—
	Total equity method investments	$	518,750	$	—

CONVERTIBLE_NOTE_PAYABLE_Table

CONVERTIBLE NOTE PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2014
CONVERTIBLE NOTE PAYABLE	'
Schedule of convertible note payable	'
	Our convertible note payable consists of the following:
		September 30,			December 31,
		2014			2013
	Convertible note payable-Typenex	$	1,657,500		$	—
	Less – current portion		(282,500	)		—
	Convertible note payable-noncurrent		1,375,000			—
	Less – unamortized discount		(659,082	)		—
	Convertible note payable-noncurrent, net	$	715,918		$	—
	Convertible note payable-current portion	$	282,500		$	—
	Less – unamortized discount		(235,417	)		—
	Convertible notes payable-current portion, net	$	47,083		$	—
Schedule of unamortized debt discount applicable to the initial borrowing	'
	We are amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.
					Nine Months Ended
					September 30,
					2014
	Debt discount - OID				$	25,000
	Debt discount – Warrant #1					118,373
	Debt discount – conversion feature					151,937
	Less: loss on origination of derivative					(12,810	)
	Debt discount – beginning balance					282,500
	Less: amortization of debt discount					(47,083	)
	Unamortized debt discount – end of period				$	235,417
Schedule of unamortized debt discount applicable to the noncurrent portion of the Note	'
	Our unamortized debt discount applicable to the noncurrent portion of the Note consists of:
					Nine Months Ended
					September 30,
					2014
	Debt discount - OID				$	125,000
	Debt discount – Warrants #2 - #6					576,151
	Debt discount – beginning balance					701,151
	Less: amortization of debt discount					(42,069	)
	Unamortized debt discount – end of period				$	659,082
Schedule of convertible note, net	'
	Our convertible note, net consists of:
					Nine Months Ended
					September 30,
					2014
	Note				$	1,657,500
	Debt discount – OID					(150,000	)
	Debt discount – Warrants					(694,524	)
	Debt discount – conversion feature					(151,937	)
	Debt discount – conversion feature expensed as loss on origination of derivative					12,810
	Convertible note, net – beginning of period					673,849
	Amortization of debt discount					89,152
	Convertible note, net – end of period				$	763,001

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
Summary of share warrants outstanding	'
	The following table summarizes our share warrants outstanding as of September 30, 2014 and December 31, 2013:
		30-Sep-14
		Number of		Weighted		Weighted
		Shares		Average		Average
				Remaining		Exercise
				Life		Price
				(years)
	Warrants outstanding, beginning of period		—		—	$	—
	Issued		3,997,692		1.8		9.75
	Exercised		—		—		—
	Expired		—		—		—
	Warrants outstanding, end of period		3,997,692		1.8	$	9.75
	Warrants exercisable, September 30, 2014		3,170,044		1.6	$	11.52

DISCONTINUED_OPERATIONS_Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Sep. 30, 2014
DISCONTINUED OPERATIONS [Abstract]	'
Schedule of Loss from Discontinued Operations	'
	The following chart details our loss from discontinued operations for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014			2013
	Revenues	$	—	$	32,278		$	20,684		$	91,144
	Operating expenses:
	Selling, general and administrative		—		30,870			63,872			56,601
	Depreciation		—		6,986			—			20,299
	Loss on disposal of assets		—		—			15,704			—
	Total operating expenses		—		37,856			79,576			76,900
	Income (loss) from discontinued operations, before income taxes		—		(5,578	)		(58,892	)		14,244
	Provision for income taxes		—		—			—			—
	Income (loss) from discontinued operations, net of income taxes	$	—	$	(5,578	)	$	(58,892	)	$	14,244

BUSINESS_ORGANIZATION_AND_NATU1

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Sep. 30, 2014	Mar. 26, 2014	Dec. 31, 2013
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]	'	'	'	'
Amount of payable owed to former officer and director, exchanged for assets sold	$15,000	'	'	'
Number of common shares issued in exchange for certain intellectual property	38,690,000	'	'	'
Total number of common shares previously outstanding, cancelled during period	'	'	41,690,000	'
Common stock, shares outstanding	'	43,800,000	43,620,000	6,020,000	[1]
[1]	The number of outstanding common shares has been adjusted for a four-for-one forward split that occurred on March 21, 2014

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
			Minimum [Member]	Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'	'
Cash equivalents	'	'	'	'
Allowance for doubtful accounts	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Estimated useful lives of equipment	'	'	'3 years	'5 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Convertible notes [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per share	337,569	'	337,569	'
Warrants to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of diluted net loss per share	997,692	'	3,997,692	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Customer A [Member]

Customer A [Member]

Customer A [Member]

Customer A [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer C [Member]

Customer C [Member]

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk percentage

82.00%

'

82.00%

'

10.00%

'

10.00%

'

43.00%

'

57.00%

'

GOING_CONCERN_Details

GOING CONCERN (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
GOING CONCERN [Abstract]	'	'	'	'	'
Net loss (income)	$706,638	$27,272	$1,339,858	$18,227	'
Net cash used in operating activities	'	'	1,093,057	23,060	'
Working capital deficit	306,674	'	306,674	'	'
Accumulated deficit	$1,496,461	'	$1,496,461	'	$156,603

INVESTMENTS_IN_NONMARKETABLE_E2

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Narrative) (Details) (WeedMD RX Inc. (''WMD'') [Member])	0 Months Ended	1 Months Ended
	30-May-14	31-May-14	31-May-14	1-May-14	1-May-14
		USD ($)	CAD	USD ($)	CAD
Schedule of Cost-method Investments [Line Items]	'	'	'	'	'
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500	'	'	'	'
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000	'	'	'	'
Equity investment	'	4.29%	'	'	'
Exercise price of warrants received to purchase shares	'	'	0.5	'	'
Minimum number of Series A Warrants exercised that would require all warrants received to be exercised	'	800,000	'	'	'
Common shares, price per share	'	'	'	$0.50	0.5
Warrants, price per warrant	'	$0.10	'	'	'
Value assigned to the cost of the common shares classified as a long term asset	'	$593,750	'	'	'
Fair value assigned as the cost to the warrants classified as a current asset	'	$300,000	'	'	'

INVESTMENTS_IN_NONMARKETABLE_E3

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Schedule of Assumptions) (Details) (Cost-method Investments [Member], Warrant [Member], WeedMD RX Inc. (''WMD'') [Member])	9 Months Ended
	Sep. 30, 2014
Cost-method Investments [Member] | Warrant [Member] | WeedMD RX Inc. (''WMD'') [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Pricing model	'Black Scholes
Risk free interest rate	0.60%
Expected term	'6 months
Expected volatility	70.00%
Expected dividends	0.00%

PREPAID_EXPENSES_AND_OTHER_ASS2

PREPAID EXPENSES AND OTHER ASSETS (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
PREPAID EXPENSES AND OTHER ASSETS [Abstract]	'	'
Prepaid investor relations services	$162,000	'
Prepaid accounting fees	550	'
Interest receivable	25,900	'
Total prepaid expenses and other assets	$188,450	'

EQUIPMENT_Details

EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
EQUIPMENT [Abstract]	'	'
Equipment	'	$131,584
Less accumulated depreciation and amortization	'	-113,968
Equipment, net	'	$17,616

EQUITY_METHOD_INVESTMENTS_Sche

EQUITY METHOD INVESTMENTS (Schedule of equity method investments) (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 14, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 15, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 25, 2014

Aug. 15, 2014

Dec. 31, 2013

Lone Mountain [Member]

Lone Mountain [Member]

Lone Mountain [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Schedule of Equity Method Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest owned (as a percentage)

'

'

25.00%

25.00%

'

15.00%

15.00%

'

33.00%

33.00%

'

50.00%

50.00%

50.00%

'

Equity method investments

$282,000

'

$50,000

$50,000

'

$45,000

'

'

$99,000

'

'

$88,000

$88,000

$88,000

'

EQUITY_METHOD_INVESTMENTS_Narr

EQUITY METHOD INVESTMENTS (Narrative) (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 14, 2014

Dec. 31, 2013

Aug. 31, 2014

Sep. 30, 2014

Aug. 15, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 31, 2014

Dec. 31, 2013

Aug. 15, 2014

Sep. 30, 2014

Aug. 25, 2014

Dec. 31, 2013

Lone Mountain [Member]

Lone Mountain [Member]

Lone Mountain [Member]

Oms [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Cannibinoid Research And Development Company Limited [Member]

Schedule of Equity Method Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest acquired (as a percentage)

'

'

25.00%

25.00%

'

'

15.00%

15.00%

'

33.00%

33.00%

'

50.00%

50.00%

50.00%

'

Equity method investments

$282,000

'

$50,000

$50,000

'

'

$45,000

'

'

$99,000

'

'

$88,000

$88,000

$88,000

'

Commitment to provide services accounted as deferred revenue

'

'

'

'

'

144,000

'

'

'

'

'

'

'

'

'

'

Shares of common stock issuable for acquisition of interest

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

Common stock not yet issued

'

'

'

'

'

'

'

'

'

'

'

'

'

$88,000

'

'

NOTES_AND_INTEREST_RECEIVABLE_

NOTES AND INTEREST RECEIVABLE (Details) (Typenex Co-Investment, LLC [Member], USD $)	0 Months Ended	3 Months Ended	9 Months Ended
	Aug. 13, 2014	Sep. 30, 2014	Sep. 30, 2014
Five unsecured Investor Notes	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Notes receivable, face amount	$1,250,000	'	'
Notes receivable, interest rate (as a percent)	8.00%	'	'
Minimum share price for 20 consecutive days used for exercise of right to call notes receivables	$6	'	'
Period of share price used for exercise of right to call notes receivables	'20 days	'	'
Interest income	'	13,150	13,150
Investor Notes	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Notes receivable, face amount	$250,000	$250,000	$250,000

FAIR_VALUE_MEASUREMENTS_Schedu

FAIR VALUE MEASUREMENTS (Schedule of liabilities carried at fair value measured on a recurring basis) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	$165,488	'
Recurring basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	165,488	'
Recurring basis [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	'	'
Recurring basis [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	'	'
Recurring basis [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Derivative liability	$165,488	'

FAIR_VALUE_MEASUREMENTS_Narrat

FAIR VALUE MEASUREMENTS (Narrative) (Details) (Convertible Note [Member], Typenex Co-Investment, LLC [Member], USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Aug. 15, 2014
Convertible Note [Member] | Typenex Co-Investment, LLC [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Debt instrument initial borrowing	'	'	$282,500
Accrued interest	$21,312	$21,312	'

FAIR_VALUE_MEASUREMENTS_Schedu1

FAIR VALUE MEASUREMENTS (Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis) (Details) (Derivative instruments related to embedded conversion features [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			Debt discount [Member]	Interest expense [Member]	Loss on derivative liability [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis	'	'	'	'	'
Derivative liability at the beginning of the period	$165,488	'	'	'	'
Additions to derivative liability recorded in statements of operations	'	'	151,937	11,609	1,942
Derivative liability at the end of the period	$165,488	'	'	'	'

FAIR_VALUE_MEASUREMENTS_Schedu2

FAIR VALUE MEASUREMENTS (Schedule of key inputs in valuation of embedded conversion features) (Details) (Recurring basis [Member], Derivative instruments related to embedded conversion features [Member], Level 3 [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Dividend yield	'
Exercise price (in dollars per share)	$3
Minimum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Risk-free interest rate (as a percent)	0.43%
Volatility (as a percent)	146.00%
Expected life in years	'1 year 11 months 16 days
Maximum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Risk-free interest rate (as a percent)	0.58%
Volatility (as a percent)	157.00%
Expected life in years	'2 years 1 month 2 days

FAIR_VALUE_MEASUREMENTS_Schedu3

FAIR VALUE MEASUREMENTS (Schedule of components of derivative financial instruments on condensed balance sheets) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'	'
Embedded derivative liability in convertible debt	$153,879	'
Embedded derivative liability in interest payable	11,609	'
Total derivative liability	$165,488	'

DEFERRED_REVENUE_Details

DEFERRED REVENUE (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

30-May-14

Sep. 30, 2014

Sep. 30, 2014

31-May-14

Dec. 31, 2013

Aug. 31, 2014

Sep. 30, 2014

Aug. 15, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 31, 2014

Dec. 31, 2013

WeedMD [Member]

WeedMD [Member]

WeedMD [Member]

WeedMD [Member]

WeedMD [Member]

Oms [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

Om of Medicine, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

OM of Illinois, LLC [Member]

Deferred Revenue Arrangement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue current and noncurrent

'

'

'

$818,750

$818,750

'

'

'

$45,000

'

'

$99,000

'

'

Less - current portion

-444,000

'

'

300,000

300,000

'

'

'

'

'

'

'

'

'

Total equity method investments

518,750

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares received in exchange for future consulting services and use of our intellectual property

'

'

1,187,500

'

'

'

'

'

'

'

'

'

'

'

Warrants received in exchange for future consulting services and use of our intellectual property

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

Fair value of securities recorded as deferred revenue

'

'

893,750

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue recognized per month

'

'

'

25,000

25,000

'

'

'

'

'

'

'

'

'

Total deferred revenue recognized

'

'

'

$75,000

$75,000

'

'

$144,000

'

'

'

'

'

'

Interest acquired (as a percentage)

'

'

'

'

'

4.29%

'

'

15.00%

15.00%

'

33.00%

33.00%

'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (Unsecured, demand promissory note, WeedMD [Member], USD $)	Sep. 30, 2014	Jul. 07, 2014
Unsecured, demand promissory note | WeedMD [Member]	'	'
Short-term Debt [Line Items]	'	'
Debt instrument, face amount	'	$175,000
Debt instrument, interest rate	'	5.00%
Accrued interest payable	$2,067	'

CONVERTIBLE_NOTE_PAYABLE_Detai

CONVERTIBLE NOTE PAYABLE (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Aug. 13, 2014

Aug. 13, 2014

Aug. 13, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Aug. 13, 2014

Aug. 13, 2014

Aug. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 15, 2014

Aug. 15, 2014

Sep. 30, 2014

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Convertible Note [Member]

Investor Notes

Investor Notes

Warrant [Member]

Item

Minimum [Member]

Warrant [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Typenex Co-Investment, LLC [Member]

Item

Item

Initial tranche [Member]

Initial tranche [Member]

Five subsequent tranches [Member]

Five subsequent tranches [Member]

Item

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note payable

$1,657,500

'

$1,657,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less - current portion

-282,500

'

-282,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note payable-noncurrent

1,375,000

'

1,375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less - unamortized discount

-659,082

'

-659,082

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note payable-noncurrent, net

715,918

'

715,918

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible note payable-current portion

282,500

'

282,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less - unamortized discount

-235,417

'

-235,417

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible notes payable-current portion, net

47,083

'

47,083

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Debt instrument, face amount

'

'

'

'

'

'

'

'

'

'

50,000

'

'

1,657,500

'

1,657,500

1,657,500

'

'

'

'

Original issue discount

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

25,000

-150,000

-150,000

'

'

'

'

Legal expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500

32,500

'

'

'

'

'

'

Payment of brokerage fees

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

Number of warrants issued to purchase shares of common stock

'

'

'

'

'

'

'

997,692

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares for which warrant became exercisable

'

'

'

'

'

'

'

170,044

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of tranches in which remaining warrants are exercisable into number of shares

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$3

'

'

'

'

'

'

'

'

Warrant term

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Frequency of number of shares of common stock issuable under the Warrants

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, term

'

'

'

'

'

'

'

'

'25 months

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, price per share

'

'

'

'

'

'

'

'

$3

'

$0.01

$3

'

'

$3

'

'

'

'

'

'

Minimum amount payable plus the sum of any accrued and unpaid interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,875

'

'

'

'

Conversion Factor (as a percent)

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

Number of lowest closing bid prices in specified trading days immediately preceding the applicable conversion

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

Number of trading days immediately preceding the applicable conversion

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

Measurement price (in dollars per share)

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

Reduction in conversion factor (as a percent)

'

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

Percentage of amount required to be payable in cash

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12500.00%

12500.00%

'

'

'

'

Net cash proceeds received from initial borrowing

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

225,000

'

'

'

'

'

'

Debt instrument initial borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,500

'

'

'

'

'

'

Number of tranches in which debt instruments can be converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

'

'

'

'

5

'

Tranche amount of debt instrument to be converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,500

275,000

'

Amount of conversion eligible initial tranche

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,500

'

'

'

Tranche amount of debt instrument to be converted if and when corresponding Investor Notes will be repaid to the entity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

275,000

Notes receivable, face amount

'

'

'

'

'

250,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of the first Warrant issued recorded as debt discount under initial borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,373

118,373

'

'

'

'

Loss on origination of derivative liability

-1,942

'

-1,942

'

'

'

'

'

'

'

'

'

'

'

12,810

'

'

'

'

'

'

Portion of fair value of initial borrowing conversion feature recorded as debt discount under initial borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

139,127

'

'

'

'

'

'

Unamortized debt discount applicable to initial borrowing [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount - OID

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

25,000

'

'

'

'

Debt discount - Warrant #1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

118,373

118,373

'

'

'

'

Debt discount - conversion feature

'

'

'

'

'

'

'

'

'

'

'

'

'

'

151,937

'

151,937

'

'

'

'

Less: loss on origination of derivative

-12,810

'

-12,810

'

'

'

'

'

'

'

'

'

'

'

'

'

-12,810

'

'

'

'

Debt discount - beginning balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,500

'

'

'

'

Less: amortization of debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-47,083

'

'

'

'

Unamortized debt discount - end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

282,500

235,417

235,417

'

'

'

'

Debt instrument remaining borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,375,000

'

'

'

'

'

'

Original issue discount under remaining borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

'

'

'

'

'

'

Fair value of the Warrant issued recorded as debt discount under remaining borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

576,151

'

'

'

'

'

'

Total debt discount under remaining borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

701,151

'

'

'

'

'

'

Unamortized debt discount applicable to the noncurrent portion of the Note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount - OID

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

125,000

'

'

'

'

Debt discount - Warrants #2 - #6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

576,151

576,151

'

'

'

'

Debt discount - beginning balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

701,151

'

'

'

'

Less: amortization of debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

42,069

'

'

'

'

Unamortized debt discount - end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

659,082

659,082

'

'

'

'

Components of convertible debt, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note

'

'

'

'

'

'

'

'

'

'

50,000

'

'

1,657,500

'

1,657,500

1,657,500

'

'

'

'

Debt discount - OID

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

25,000

-150,000

-150,000

'

'

'

'

Debt discount - Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-694,524

-694,524

'

'

'

'

Debt discount - conversion feature

'

'

'

'

'

'

'

'

'

'

'

'

'

'

151,937

'

151,937

'

'

'

'

Debt discount - conversion feature expensed as loss on origination of derivative

-12,810

'

-12,810

'

'

'

'

'

'

'

'

'

'

'

'

'

-12,810

'

'

'

'

Convertible note, net - beginning of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

673,849

'

'

'

'

Amortization of debt discount

89,152

'

89,152

'

'

'

'

'

'

'

'

'

'

'

'

89,152

89,152

'

'

'

'

Convertible note, net - end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

763,001

763,001

'

'

'

'

Debt discount amortization and interest expense

89,152

'

89,152

'

'

'

'

'

'

'

'

'

'

'

'

89,152

89,152

'

'

'

'

Accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,312

21,312

'

'

'

'

Fair value of the conversion feature applicable to accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$11,609

$11,609

'

'

'

'

NOTES_PAYABLE_RELATED_PARTIES_

NOTES PAYABLE, RELATED PARTIES (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Aug. 13, 2014	Dec. 31, 2011	Sep. 30, 2014	Dec. 31, 2013
			Convertible Debt [Member]	Convertible Debt [Member]	Convertible Debt [Member]	Former President [Member]	Former President [Member]	Former President [Member]
						Revolving Promissory Note [Member]	Revolving Promissory Note [Member]	Revolving Promissory Note [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'
Debt instrument, face amount	'	'	'	$50,000	'	$100,000	'	'
Debt instrument, interest rate	'	'	'	'	'	6.00%	'	'
Debt instrument, maturity date	'	'	'	'	'	31-Dec-13	'	'
Convertible note payable, related party	'	$50,000	'	'	'	'	'	'
Number of common stock shares debt instrument can be converted to	'	'	'	10,000,000	'	'	'	'
Debt conversion, price per share	'	'	'	$0.01	$3	'	'	'
Debt instrument, conversion date	'	'	24-Feb-14	'	'	'	'	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)	1 Months Ended
	Mar. 31, 2014	Feb. 28, 2014	Sep. 30, 2014	2-May-14	1-May-14	Dec. 31, 2013
STOCKHOLDERS' EQUITY [Abstract]	'	'	'	'	'	'
Common stock sold under stock purchase agreement, representing approximately 87% of the issued and outstanding shares of the Company	'	10,000,000	'	'	'	'
Number of units sold through equity offering	600,000	'	'	'	'	'
Proceeds from sale of units	$900,000	'	'	'	'	'
Per share price A Warrant holders can purchase each share of the Company's common stock during the two year period commencing April 1, 2014	$7.50	'	'	'	'	'
Per share price B Warrant holders can purchase each share of the Company's common stock during the three year period commencing April 1, 2014	$15	'	'	'	'	'
Preferred stock, shares authorized	'	'	10,000,000	10,000,000	5,000,000	10,000,000
Preferred stock, par value per share	'	'	'	'	$0.00	'
Preferred stock, no par value	'	'	'	'	'	'
Common stock, shares authorized	'	'	100,000,000	100,000,000	50,000,000	100,000,000
Common stock, par value per share	'	'	'	'	$0.00	'
Common stock, no par value	'	'	'	'	'	'

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (USD $)	0 Months Ended				9 Months Ended
	Sep. 17, 2014	Aug. 25, 2014	Aug. 14, 2014	Aug. 15, 2014	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity [Line Items]	'	'	'	'	'	'
Number of shares of common stock issued for services	150,000	'	10,000	20,000	'	'
Value of shares of common stock issued for services	$162,000	'	$9,200	$24,800	'	'
Number of shares of common stock committed to be issued for services	'	40,000	'	'	'	'
Value of shares of common stock committed to be issued for services	'	88,000	'	'	'	'
Equity method investments	'	'	'	'	282,000	'
Number of Shares	'	'	'	'	'	'
Warrants outstanding, beginning of period (in shares)	'	'	'	'	'	'
Issued (in shares)	'	'	'	'	3,997,692	'
Exercised (in shares)	'	'	'	'	'	'
Expired (in shares)	'	'	'	'	'	'
Warrants outstanding, end of period (in shares)	'	'	'	'	3,997,692	'
Warrants exercisable at the end of the period (in shares)	'	'	'	'	3,170,044	'
Weighted Average Remaining Life (years)	'	'	'	'	'	'
Warrants outstanding, beginning of period	'	'	'	'	'1 year 9 months 18 days	'
Issued	'	'	'	'	'1 year 9 months 18 days	'
Warrants exercisable at the end of the period	'	'	'	'	'1 year 7 months 6 days	'
Warrants outstanding, end of period	'	'	'	'	'1 year 9 months 18 days	'
Weighted Average Exercise Price	'	'	'	'	'	'
Warrants outstanding, beginning of period (in dollars per share)	'	'	'	'	'	'
Issued (in dollars per share)	'	'	'	'	$9.75	'
Exercised (in dollars per share)	'	'	'	'	'	'
Warrants outstanding, end of period (in dollars per share)	'	'	'	'	$9.75	'
Warrants exercisable at the end of the period (in dollars per share)	'	'	'	'	$11.52	'
Cannibinoid Research And Development Company Limited [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Ownership interest (as a percent)	'	50.00%	'	50.00%	50.00%	'
Equity method investments	'	88,000	'	88,000	88,000	'
Prepaid Expenses and Other Current Assets [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Value of shares of common stock issued for services	162,000	'	'	'	'	'
Selling and Marketing Expense [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Value of shares of common stock issued for services	'	'	9,200	'	'	'
General and Administrative Expense [Member]	'	'	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'	'	'
Value of shares of common stock issued for services	'	'	'	$24,800	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	31-May-14	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Consultancy agreement, term	'6 months	'	'	'	'
Consultancy agreement, initial payment	$50,000	'	'	'	'
Consultancy agreement, additional payments	50,000	'	'	'	'
Shares issued for consultancy agreement	100,000	'	'	'	'
Research and development expenses	'	94,751	'	170,805	'
Cash payment obligations	'	200,000	'	200,000	'
Accrued expenses	'	$100,000	'	$100,000	'

DISCONTINUED_OPERATIONS_Detail

DISCONTINUED OPERATIONS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Dec. 31, 2013
DISCONTINUED OPERATIONS [Abstract]	'	'	'	'	'	'
Amount of payable owed to former officer and director, exchanged for assets sold	'	'	'	'	$15,000	'
Revenues	'	32,278	20,684	91,144	'	'
Operating expenses:	'	'	'	'	'	'
Selling, general and administrative	'	30,870	63,872	56,601	'	'
Depreciation	'	6,986	'	20,299	'	'
Loss on disposal of assets	'	'	15,704	'	'	'
Total operating expenses	'	37,856	79,576	76,900	'	'
Income (loss) from discontinued operations, before income taxes	'	-5,578	-58,892	14,244	'	'
Provision for income taxes	'	'	'	'	'	'
Income (loss) from discontinued operations, net of income taxes	'	-5,578	-58,892	14,244	'	'
Equipment	'	'	'	'	'	$17,616

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], USD $)	1 Months Ended
	Oct. 22, 2014
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Number of shares of common stock issued	50,000
Value of shares of common stock issued	$24,000